Helpful Resources

For patients, families & friends

Find your local chapter

Information center

Glossary
Know the terms, understand your care

ClinicalTrials.gov
A service of the U.S. National Institute of Health

Help the ALF in our challenge to win this $50,000 grant from the Pepsi Refresh Project by voting now and voting often. Our aim is to Empower Youth to Fight Liver Disease. You can help us by voting now. Click Here!

Join ALF Online

Connect with the ALF community online.

As a member, you can:

Invite your friends
Give gifts

and more!

Visit us on Facebook

See us on YouTube

ALF Brochures

Download digital brochures

Order printed brochures

Home > Educational Resources > Liver Disease Info > Clinical Trials

Clinical Trials

The U.S. government hosts a comprehensive online database of medical research on all diseases at ClinicalTrials.gov. Some examples of ClinicalTrials.gov studies currently recruiting participants are listed below.

The American Liver Foundation Society Clinical Trial Disclaimer

Information you receive through ALF’s Clinical Trial Service is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Therefore, it is important to discuss the included information with your physician. Due to clinical trial protocols and specific eligibility criteria, the listings may change and/or may no longer be actively accruing patients.

Your physician is the only one who can determine if you meet the specific eligibility criteria listed in these trials. If you and your physician decide that you may benefit from one of the studies, your physician may need to contact the principal investigator in charge of the study to discuss your medical history and current health status.

ALF does not provide medical or other healthcare opinions or services. The enclosure of another organization's / hospital's resource(s) does not indicate or imply that ALF endorses, recommends, or favors the enclosed information.

If you have any questions about our organization, please don't hesitate to call the American Liver Foundation at 212-668-1000 between 9am and 5pm EST. For information on liver disease, please dial 1-800-GO-LIVER (1-800-465-4837) or visit our online Liver Disease Information Center.

Celsion's HEAT Study Now Enrolling Recently Diagnosed HCC Patients In Clinical Trials

Celsion Corporation is an oncology drug development company which develops targeted chemotherapeutic treatments based on a unique heat-activated liposomal technology. Celsion is currently enrolling patients in a global Phase III clinical trial - the HEAT Study - which is designed to demonstrate the safety and efficacy of ThermoDox® in hepatocellular carcinoma (HCC) patients. The HEAT study involves an investigational anti-cancer drug, called ThermoDox®, used in combination with an approved medical device for radiofrequency ablation (RFA) in the liver.

The study will be the largest investigation of RFA in HCC and will involve approximately 600 patients in over 40 research institutions in seven countries and regions.

ThermoDox is designed as a heat-activated liposomal technology that is administered intravenously. When used in combination with RFA to ablate tumors, high concentrations of doxorubicin are released directly to the tumor and the surrounding liver tissue. The primary endpoint of the trial is progression-free survival.

For more information, write to mmasotti@celsion.com or call 443-259-4894. Details on the HEAT study can be found online.

Page updated: April 8th, 2009